Suchergebnisse - "Naehrlich, Lutz"

PubPharm (81)

1

Cystic fibrosis in Europe : improved lung function and longevity - reasons for cautious optimism, but challenges remain

enthalten in: The European respiratory journal | 2024

von Kerem, E. | Orenti, A. | Adamoli, A. | +4

CommentIn: Eur Respir J. 2024 Mar 7;63(3):. - PMID 38453247

2

Effectiveness of lumacaftor/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression : Interim results from an ongoing registry-based study

enthalten in: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 2024

von Kim, C. | Higgins, M. | Liu, L. | +28

3

Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis

enthalten in: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases | 2024

von Dittrich, A. | Sieber, S. | Naehrlich, L. | +4

4

Data accuracy, consistency and completeness of the national Swiss cystic fibrosis patient registry : Lessons from an ECFSPR data quality project

enthalten in: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 2023

von Wolf, L. | Usemann, J. | Collaud, E. | +29

5

Nonsense mutations accelerate lung disease and decrease survival of cystic fibrosis children

enthalten in: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society | 2023

von Orenti, A. | Pranke, I. | Faucon, C. | +31

6

Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis : real-world evidence from the German CF Registry

enthalten in: The Lancet regional health. Europe | 2023

von Sutharsan, S. | Dillenhoefer, S. | Welsner, M. | +104

7

Effects of Lumacaftor/Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years of Age Homozygous for F508del-CFTR : A Phase 2 Placebo-controlled Clinical Trial

enthalten in: Annals of the American Thoracic Society | 2023

von Stahl, M. | Roehmel, J. | Eichinger, M. | +14

8

ABCA3-related interstitial lung disease beyond infancy

enthalten in: Thorax | 2023

von Li, Y. | Seidl, E. | Knoflach, K. | +37

9

Risk factors for forced expiratory volume in 1 s decline in European patients with cystic fibrosis : data from the European Cystic Fibrosis Society Patient Registry

enthalten in: ERJ open research | 2023

von Hatziagorou, E. | Fieuws, S. | Orenti, A. | +7

10

Survival-adjusted FEV1 and BMI percentiles for patients with cystic fibrosis before the era of triple CFTR modulator therapy in Germany

enthalten in: Respiration | May 2023

von Dittrich, A. | Dumke, M. | Kapl, F. | +8

1
2
3
4
5
6
7
8
9
Nächster »
[9]